Huirong Fan

Dr. Huirong Fan


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Chinese Journal of Natural Medicines
Verified
Journal Article
Closed access
CLCui-Ping Liao
Cui-Ping Liao
XLXing-Chao Liu
Xing-Chao Liu
SDShiqi Dong
Shiqi Dong
MAMing An
Ming An
LZLu Zhao
Lu Zhao
CLChang-Xiao Liu
Chang-Xiao Liu

1 January 2017 in Journal of Chromatography B
Verified
Journal Article
Closed access
HFHuirong Fan
Huirong Fan
ZHZhanxing Hu
Zhanxing Hu
RLRuixing Li
Ruixing Li
SDShiqi Dong
Shiqi Dong
YGYuan Gu
Yuan Gu
CLChangxiao Liu
Changxiao Liu

10 April 2024 in Journal of Asian Natural Products Research
Verified
Journal Article
Closed access
YWYa-Nan Wang
Ya-Nan Wang
HJHua Jin
Hua Jin
HFHuirong Fan
Huirong Fan
BWBaolian Wang
Baolian Wang
A sensitive UPLC-HRMS method was developed and validated for simultaneous quantification of four active flavonoids from Chimonanthus nitens Leaf Granules (CNLG) in biological matrix. The method was utilized in pharmacokinetic study of the four flavonoids in rats as well as other evaluation assays in vitro. It was revealed that rutin, nicotiflorin, and astragalin had poor oral bioavailability in rats possibly due to low intestinal permeability and metabolism in intestinal flora. Kaempferol underwent rapid glucuronidation and sulphation in rat plasma with medium permeability coefficient. The results provided valuable data for future research and development of CNLG flavonoids.

12 September 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
SDShi-Qi Dong
Shi-Qi Dong
FYFan Yang
Fan Yang
DZDong-Xu Zhang
Dong-Xu Zhang
LWLing-Mei Wang
Ling-Mei Wang
JLJian-Feng Liu
Jian-Feng Liu
HFHuirong Fan
Huirong Fan
Purpose: The “radiotherapy-pharmacokinetic” (“RT-PK”) phenomenon refers to the fact that radiation can significantly alter the pharmacokinetic behavior of a drug. At present, it is not clear whether there is an “RT-PK” phenomenon that can affect apatinib during concurrent chemoradiotherapy. In this study, we used a rat irradiation model to study the effects of X-ray radiation on absorption, tissue distribution, and excretion of apatinib.Method: Healthy Sprague-Dawley (SD) rats were randomly divided into control and radiation groups. The radiation group was given an appropriate dose of abdominal X-ray radiation, while the control group was not given irradiation. After 24 h of recovery, both groups were given apatinib solution 45 mg/kg by gavage. A quantitative LC-MS/MS method was developed to determine the concentration of apatinib in the rats, so as to compare the differences between the control and radiation groups and thus investigate the modulating effect of radiation on the pharmacokinetics of apatinib in rats.Results: After abdominal X-ray irradiation, the area under the curve (AUC0-t) of apatinib in rat plasma decreased by 33.8% and 76.3% at 0.5 and 2 Gy, respectively. Clearance (CL) and volume of distribution (Vd) increased and were positively correlated with radiation dose. X-ray radiation significantly reduced the concentration of apatinib in the liver and small intestine, and there was no tissue accumulation. In excretion studies, we found that X-ray radiation reduced the cumulative excretion of apatinib in feces and urine by 11.24% and 86.17%, respectively.Conclusion: Abdominal X-ray radiation decreased plasma exposure, tissue distribution, and excretion of apatinib in rats, suggesting that the RT-PK phenomenon affects apatinib. We speculate that this RT-PK phenomenon is closely related to changes in metabolic enzymes in vivo. In clinical practice, when apatinib is combined with radiotherapy, attention should be paid to adjusting the dose of apatinib and optimizing the treatment plan to alleviate the adverse effects of this RT-PK phenomenon.

24 September 2019 in Xenobiotica
Verified
Journal Article
Closed access
HFHuirong Fan
Huirong Fan
AZAijie Zhang
Aijie Zhang
CLCuiping Liao
Cuiping Liao
YYYuanhui Yang
Yuanhui Yang
LZLihua Zhang
Lihua Zhang
CLChangxiao Liu
Changxiao Liu
The objective of this study was to clarify the species differences of pharmacokinetics of Y101 (N-[N-benzoyl-O-(2-dimethylaminoethyl)-l-tyrosyl]-l-phenylalaninol hydrochloride), a derivative of her...

20 February 2023 in Molecules
Verified
Journal Article
Open access
PDF file
AZAijie Zhang
Aijie Zhang
FYFanlong Yang
Fanlong Yang
YYYang Yuan
Yang Yuan
CLCai Li
Cai Li
XHXiaokui Huo
Xiaokui Huo
JZJiang Zheng
Jiang Zheng
Bentysrepinine (Y101) is a novel phenylalanine dipeptide for the treatment of hepatitis B virus. Renal excretion played an important role in the elimination of Y101 and its metabolites, M8 and M9, in healthy Chinese subjects, although the molecular mechanisms of renal excretion and potential drug–drug interactions (DDIs) remain unclear. The present study aimed to determine the organic anion transporters (OATs) involved in the renal disposition of Y101 and to predict the potential DDI between Y101 and entecavir, the first-line agent against HBV and a substrate of OAT1/3. Pharmacokinetic studies and uptake assays using rat kidney slices, as well as hOAT1/3-HEK293 cells, were performed to evaluate potential DDI. The co-administration of probenecid (an inhibitor of OATs) significantly increased the plasma concentrations and area under the plasma concentration–time curves of M8 and M9 but not Y101, while reduced renal clearance and the cumulative urinary excretion of M8 were observed in rats. The time course of Y101 and M8 uptake via rat kidney slices was temperature-dependent. Moreover, the uptake of M8 was inhibited significantly by probenecid and benzylpenicillin, but not by p-aminohippurate or tetraethyl ammonium. M8 was found to be a substrate of hOAT3, but Y101 is not a substrate of either hOAT1 or hOAT3. Additionally, the entecavir inhibited the uptake of M8 in the hOAT3-transfected cells and rat kidney slices in vitro. Interestingly, no significant changes were observed in the pharmacokinetic parameters of Y101, M8 or entecavir, regardless of intravenous or oral co-administration of Y101 and entecavir in rats. In conclusion, M8 is a substrate of OAT3 in rats and humans. Furthermore, M8 also mediates the DDI between Y101 and entecavir in vitro, mediated by OAT3. We speculate that it would be safe to use Y101 with entecavir in clinical practice. Our results provide useful information with which to predict the DDIs between Y101 and other drugs that act as substrates of OAT3.